158 related articles for article (PubMed ID: 11037108)
1. Characterization of transgenic mouse strains using six human hepatic cytochrome P450 probe substrates.
Mankowski DC; Lawton MP; Ekins S
Xenobiotica; 2000 Aug; 30(8):745-54. PubMed ID: 11037108
[TBL] [Abstract][Full Text] [Related]
2. Metabolism of human cytochrome P450 marker substrates in mouse: a strain and gender comparison.
Löfgren S; Hagbjörk AL; Ekman S; Fransson-Steen R; Terelius Y
Xenobiotica; 2004 Sep; 34(9):811-34. PubMed ID: 15742976
[TBL] [Abstract][Full Text] [Related]
3. Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat.
Kobayashi K; Urashima K; Shimada N; Chiba K
Biochem Pharmacol; 2002 Mar; 63(5):889-96. PubMed ID: 11911841
[TBL] [Abstract][Full Text] [Related]
4. The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6.
Mankowski DC
Drug Metab Dispos; 1999 Sep; 27(9):1024-8. PubMed ID: 10460802
[TBL] [Abstract][Full Text] [Related]
5. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
[TBL] [Abstract][Full Text] [Related]
6. Metabolism of tauromustine in liver and lung microsomes from various species.
Tuvesson H; Gunnarsson PO; Seidegård J
Xenobiotica; 1999 Aug; 29(8):783-92. PubMed ID: 10553719
[TBL] [Abstract][Full Text] [Related]
7. Activation of phenacetin O-deethylase activity by alpha-naphthoflavone in human liver microsomes.
Nakajima M; Kobayashi K; Oshima K; Shimada N; Tokudome S; Chiba K; Yokoi T
Xenobiotica; 1999 Sep; 29(9):885-98. PubMed ID: 10548449
[TBL] [Abstract][Full Text] [Related]
8. Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 isozymes.
Transon C; Lecoeur S; Leemann T; Beaune P; Dayer P
Eur J Clin Pharmacol; 1996; 51(1):79-85. PubMed ID: 8880056
[TBL] [Abstract][Full Text] [Related]
9. Regional distribution of drug-metabolizing enzyme activities in the liver and small intestine of cynomolgus monkeys.
Nakanishi Y; Matsushita A; Matsuno K; Iwasaki K; Utoh M; Nakamura C; Uno Y
Drug Metab Pharmacokinet; 2011 Jun; 26(3):288-94. PubMed ID: 21273732
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of human CYP1A2 activity in vitro by methylxanthines: potent competitive inhibition by 8-phenyltheophylline.
Murray S; Odupitan AO; Murray BP; Boobis AR; Edwards RJ
Xenobiotica; 2001 Mar; 31(3):135-51. PubMed ID: 11465391
[TBL] [Abstract][Full Text] [Related]
11. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
Butler AM; Murray M
J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
[TBL] [Abstract][Full Text] [Related]
12. Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms.
Renwick AB; Surry D; Price RJ; Lake BG; Evans DC
Xenobiotica; 2000 Oct; 30(10):955-69. PubMed ID: 11315104
[TBL] [Abstract][Full Text] [Related]
13. Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man.
Venkatakrishnan K; von Moltke LL; Duan SX; Fleishaker JC; Shader RI; Greenblatt DJ
J Pharm Pharmacol; 1998 Mar; 50(3):265-74. PubMed ID: 9600717
[TBL] [Abstract][Full Text] [Related]
14. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the substrate specificities of human liver cytochrome P450s 2C9 and 2C18: application to the design of a specific substrate of CYP 2C18.
Minoletti C; Dijols S; Dansette PM; Mansuy D
Biochemistry; 1999 Jun; 38(24):7828-36. PubMed ID: 10387023
[TBL] [Abstract][Full Text] [Related]
16. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes.
Yamazaki H; Shimada T
Arch Biochem Biophys; 1997 Oct; 346(1):161-9. PubMed ID: 9328296
[TBL] [Abstract][Full Text] [Related]
17. Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin.
Heyn H; White RB; Stevens JC
Drug Metab Dispos; 1996 Sep; 24(9):948-54. PubMed ID: 8886603
[TBL] [Abstract][Full Text] [Related]
18. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
[TBL] [Abstract][Full Text] [Related]
19. Interlaboratory comparison of the assessment of P450 activities in human hepatic microsomal samples.
Boobis AR; McKillop D; Robinson DT; Adams DA; McCormick DJ
Xenobiotica; 1998 May; 28(5):493-506. PubMed ID: 9622851
[TBL] [Abstract][Full Text] [Related]
20. Construction of Salmonella typhimurium YG7108 strains, each coexpressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase.
Fujita K; Nakayama K; Yamazaki Y; Tsuruma K; Yamada M; Nohmi T; Kamataki T
Environ Mol Mutagen; 2001; 38(4):329-38. PubMed ID: 11774365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
